



TRUST ORACEA® (doxycycline, USP) 40 MG* CAPSULES

30 MG IMMEDIATE AND 10 MG DELAYED RELEASE

ORACEA Capsules can help reduce the bumps and blemishes of your rosacea, while fitting easily into your daily routine. As rosacea is caused by inflammation under the skin, not by a bacterial infection, an antibiotic dose may not be needed. Always talk to your dermatologist about your medications

Here are four reasons why ORACEA Capsules can help you today:



SIMPLE AND EFFECTIVE

Help achieve clearer skin through a convenient capsule taken once a day. Those taking ORACEA Capsules in clinical trials saw significant improvements in the reduction of the bumps and blemishes of rosacea in as little as 3 weeks, and improvements continued through the full 16-week course of the study



FEWER SIDE EFFECTS

In a 16-week study comparing ORACEA Capsules with an antibiotic dose, subjects taking ORACEA Capsules had a lower incidence of unwanted gastrointestinal side effects than with doxycycline 100 mg. Those taking ORACEA Capsules experienced less nausea, vomiting or diarrhea



CONSISTENT RESULTS

Regardless of how severe your rosacea is when you start your treatment, ORACEA Capsules remains an effective rosacea treatment for your bumps and blemishes



SAFE FOR THE LONG TERM†

ORACEA Capsules are a non-antibiotic dose, and unlike higher dose doxycyclines (100 mg), did not contribute to antibiotic resistance, as shown in a 9-month study. With ORACEA Capsules, you can help manage your bumps and blemishes of rosacea over a long period of time†

In controlled clinical studies, the most commonly reported adverse events (>2%) in patients treated with ORACEA Capsules were nasopharyngitis, sinusitis, diarrhea, hypertension and aspartate aminotransferase increase.



A CONVENIENT, ONCE-DAILY TREATMENT
**YOU HAVE BEEN PRESCRIBED
 ORACEA CAPSULES FOR YOUR BUMPS
 AND BLEMISHES OF ROSACEA**

It is important that you get the medication you have been prescribed. Doxycycline in ANY non-modified release dose is not the same as ORACEA Capsules and should not be a substitute

For more information, please go to GaldermaCC.com

Special instructions:

Cleanser: _____

Sunscreen: _____

Moisturizer: _____

Other medications: _____

IMPORTANT SAFETY INFORMATION

Indication: ORACEA® (doxycycline, USP) 40 mg* Capsules are indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients. ORACEA Capsules do not lessen the facial redness caused by rosacea. **Adverse Events:** In controlled clinical studies, the most commonly reported adverse events (>2%) in patients treated with ORACEA Capsules were nasopharyngitis, sinusitis, diarrhea, hypertension and aspartate aminotransferase increase. **Warnings/Precautions:** ORACEA Capsules should not be used to treat or prevent infections. ORACEA Capsules should not be taken by patients who have a known hypersensitivity to doxycycline or other tetracyclines. ORACEA Capsules should not be taken during pregnancy, by nursing mothers, or during tooth development (up to the age of 8 years). Although photosensitivity was not observed in clinical trials, ORACEA Capsules patients should minimize or avoid exposure to natural or artificial sunlight. The efficacy of ORACEA Capsules treatment beyond 16 weeks and safety beyond 9 months have not been established

You are encouraged to report negative side effects of prescription drugs to the FDA
 Visit www.fda.gov/medwatch or call 1-800-FDA-1088

*30 mg immediate release and 10 mg delayed release beads
 †Based on safety data from a 9-month clinical trial

© 2021 Galderma Laboratories, L.P. United States, All Rights Reserved.
 All trademarks are the property of their respective owners

Galderma Laboratories, L.P.
 14501 N. Freeway, Fort Worth, TX 76177
 US-ORC-2100092 Printed in USA 10/21

Simply, download the Galderma CAREConnect Card and you may receive instant savings on your prescription and refills[†]



[†]Galderma CAREConnect is only available for commercially insured or uninsured patients. Patients who are enrolled in a government-run or government sponsored healthcare plan with a pharmacy benefit are not eligible to use the Galderma CAREConnect patient savings card

REFERENCES

1. Del Rosso JQ, et al. Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea. *J Am Acad Dermatol.* 2007;56(5):791–802.
2. Del Rosso JQ, et al. Comparison of anti-inflammatory dose doxycycline versus doxycycline 100 mg in the treatment of rosacea. *J Drugs Dermatol.* 2008;7(8):573–576.
3. Fowler JF. Anti-inflammatory dose doxycycline for the treatment of rosacea. *Expert Rev Dermatol.* 2007;2(5):523–531.
4. Preshaw PM, et al. Modified-release subantimicrobial dose doxycycline enhances scaling and root planing in subjects with periodontal disease. *J Periodontol.* 2008;79(3):440–452.
5. ORACEA [package insert]. Fort Worth, TX: Galderma Laboratories, L.P.; 2014.
6. Bhatia N. ORACEA 40 mg capsules for papulopustular rosacea. *The Dermatologist.* 2013;6(21s):1-4. Available at: <https://pdfs.semanticscholar.org/363e/66311811307ccfd9e9d8bd8b594bdaf4254.pdf>. Accessed: December 2020.
7. Theobald K, et al. Anti-inflammatory dose doxycycline (40 mg controlled-release) confers maximum anti-inflammatory efficacy in rosacea. *Skinmed.* 2007;6(5):221–226.
8. Wise RD. Sub microbial doxycycline and rosacea. *Compr Ther.* 2007;33(2):78–81.
9. Baldwin HE. Diagnosis and treatment of rosacea: state of the art. *J Drugs Dermatol.* 2012;11(6):725–730.
10. Walker C and Bradshaw M. The effect of oral doxycycline 100 mg once-daily for 14 days on the nasopharyngeal flora of healthy volunteers: a preliminary analysis. Presented at: Fall Clinical Dermatology; October 18–21, 2007; Las Vegas, NV.
11. Data on file. Oracea PK Profile. Galderma Laboratories, L.P.
12. Data on File. G.LI.04.SRE.US10148 w ADD02 CSR.

ONCE-DAILY

ORACEA®

(doxycycline, USP) 40* mg Capsules

*30 MG IMMEDIATE RELEASE & 10 MG DELAYED RELEASE BEADS
 [OR-RAY-SHA]